These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 26005168)

  • 21. Changes in plasma C-reactive protein and hemostatic factors prior to and after a first myocardial infarction with a median follow-up time of 8 years.
    Thøgersen AM; Nilsson TK; Weinehall L; Boman K; Eliasson M; Hallmans G; Jansson JH
    Blood Coagul Fibrinolysis; 2009 Jul; 20(5):340-6. PubMed ID: 19357504
    [TBL] [Abstract][Full Text] [Related]  

  • 22. C-reactive protein, bezafibrate, and recurrent coronary events in patients with chronic coronary heart disease.
    Haim M; Benderly M; Tanne D; Matas Z; Boyko V; Fisman EZ; Tenenbaum A; Zimmlichman R; Battler A; Goldbourt U; Behar S
    Am Heart J; 2007 Dec; 154(6):1095-101. PubMed ID: 18035081
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Increased monomeric CRP levels in acute myocardial infarction: a possible new and specific biomarker for diagnosis and severity assessment of disease.
    Wang J; Tang B; Liu X; Wu X; Wang H; Xu D; Guo Y
    Atherosclerosis; 2015 Apr; 239(2):343-9. PubMed ID: 25682033
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Relationship between serum level of high-sensitive C-reactive protein and extension of myocardial involvement in patients with acute myocardial infarction.
    Rashidinejad H; Hosseini SM; Moazenzadeh M; Azimzadeh BS; Mirzaeipour F; Fakhreddini K; Sheikhvatan M
    Rom J Intern Med; 2012; 50(3):211-5. PubMed ID: 23330288
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Selective apheresis of C-reactive protein: a new therapeutic option in myocardial infarction?
    Sheriff A; Schindler R; Vogt B; Abdel-Aty H; Unger JK; Bock C; Gebauer F; Slagman A; Jerichow T; Mans D; Yapici G; Janelt G; Schröder M; Kunze R; Möckel M
    J Clin Apher; 2015 Feb; 30(1):15-21. PubMed ID: 25044559
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Current trend of acute myocardial infarction in Korea (from the Korea Acute Myocardial Infarction Registry from 2006 to 2013).
    Kook HY; Jeong MH; Oh S; Yoo SH; Kim EJ; Ahn Y; Kim JH; Chai LS; Kim YJ; Kim CJ; Chan Cho M;
    Am J Cardiol; 2014 Dec; 114(12):1817-22. PubMed ID: 25438907
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mediterranean diet and inflammatory response in myocardial infarction survivors.
    Panagiotakos DB; Dimakopoulou K; Katsouyanni K; Bellander T; Grau M; Koenig W; Lanki T; Pistelli R; Schneider A; Peters A;
    Int J Epidemiol; 2009 Jun; 38(3):856-66. PubMed ID: 19244256
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Relationship between baseline inflammatory markers, antiplatelet therapy, and adverse cardiac events after percutaneous coronary intervention: an analysis from the clopidogrel for the reduction of events during observation trial.
    Dosh K; Berger PB; Marso S; van Lente F; Brennan DM; Charnigo R; Topol EJ; Steinhubl S
    Circ Cardiovasc Interv; 2009 Dec; 2(6):503-12. PubMed ID: 20031767
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of pitavastatin treatment on changes of plaque volume and composition according to the reduction of high-sensitivity C-reactive protein levels.
    Hong YJ; Jeong MH; Ahn Y; Kim SW; Bae JH; Hur SH; Ahn TH; Rha SW; Kim KS; Chae IH; Kim JH; Yun KH; Oh SK;
    J Cardiol; 2012 Oct; 60(4):277-82. PubMed ID: 22658699
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Relationship of cardiac biomarkers and reversible and irreversible myocardial injury following acute myocardial infarction as determined by cardiovascular magnetic resonance.
    Mather AN; Fairbairn TA; Artis NJ; Greenwood JP; Plein S
    Int J Cardiol; 2013 Jun; 166(2):458-64. PubMed ID: 22119118
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Association of beta-blocker therapy at discharge with clinical outcomes in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.
    Yang JH; Hahn JY; Song YB; Choi SH; Choi JH; Lee SH; Kim JH; Ahn YK; Jeong MH; Choi DJ; Park JS; Kim YJ; Park HS; Han KR; Rha SW; Gwon HC
    JACC Cardiovasc Interv; 2014 Jun; 7(6):592-601. PubMed ID: 24947717
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Usefulness of preprocedure high-sensitivity C-reactive protein to predict death, recurrent myocardial infarction, and stent thrombosis according to stent type in patients with ST-segment elevation myocardial infarction randomized to bare metal or drug-eluting stenting during primary percutaneous coronary intervention.
    Schoos MM; Kelbæk H; Kofoed KF; Køber L; Kløvgaard L; Helqvist S; Engstrøm T; Saunamäki K; Jørgensen E; Holmvang L; Clemmensen P
    Am J Cardiol; 2011 Jun; 107(11):1597-603. PubMed ID: 21439539
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Evaluation of clinical usefulness of selected laboratory markers in the prediction of myocardial infarction in patients under secondary prevention].
    Plak M; Łobos M; Religa W; Tokarek A; Bonar A; Janas B; Paradowski M
    Pol Merkur Lekarski; 2011 Jul; 31(181):9-14. PubMed ID: 21870702
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Relationship between high-sensitivity C-reactive protein and clinical functional outcome after acute ischemic stroke in a Korean population.
    Song IU; Kim JS; Kim YI; Lee KS; Jeong DS; Chung SW
    Cerebrovasc Dis; 2009; 28(6):545-50. PubMed ID: 19844093
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic significance of the Centers for Disease Control/American Heart Association high-sensitivity C-reactive protein cut points for cardiovascular and other outcomes in patients with stable coronary artery disease.
    Sabatine MS; Morrow DA; Jablonski KA; Rice MM; Warnica JW; Domanski MJ; Hsia J; Gersh BJ; Rifai N; Ridker PM; Pfeffer MA; Braunwald E;
    Circulation; 2007 Mar; 115(12):1528-36. PubMed ID: 17372173
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Inflammation study in unstable angina and myocardial infarction without ST segment elevation. Value of ultra-sensitive C-reactive protein].
    Borrás Pallé S; Gómez Martínez E; Romero Rodrigo A; Campos Ferrer C; Molina E; Valentín Segura V
    An Med Interna; 2002 Jun; 19(6):283-8. PubMed ID: 12152386
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The course of D-dimer, high-sensitivity C-reactive protein and pro-B-type natriuretic peptide in patients with non-ST-elevation myocardial infarction.
    Ghanavatian S; Stein RA; Atar D; Hole L; Agewall S
    Clin Lab; 2011; 57(9-10):771-6. PubMed ID: 22029194
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Usefulness of C-reactive protein and left ventricular function for risk assessment in survivors of acute myocardial infarction.
    Sanchis J; Bodí V; Llácer A; Núñez J; Facila L; Ruiz V; Blasco M; Sanjuán R; Chorro FJ
    Am J Cardiol; 2004 Sep; 94(6):766-9. PubMed ID: 15374783
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Early prognostic usefulness of C-reactive protein added to the Thrombolysis In Myocardial Infarction risk score in acute coronary syndromes.
    Foussas SG; Zairis MN; Lyras AG; Patsourakos NG; Tsirimpis VG; Katsaros K; Beldekos DJ; Handanis SM; Mytas DZ; Karidis KS; Tselioti PG; Prekates AA; Ambrose JA
    Am J Cardiol; 2005 Aug; 96(4):533-7. PubMed ID: 16098307
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of GM-CSF on the stem cells mobilization and plasma C-reactive protein levels in patients with acute myocardial infarction.
    Deng Z; Yang C; Deng H; Yang A; Geng T; Chen X; Ma A; Liu Z
    Int J Cardiol; 2006 Oct; 113(1):92-6. PubMed ID: 16891014
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.